Media advisory - KLOX Technologies to present innovative acne treatment technology at 2013 BioContact Québec

Klox Technologies' President and CEO to present: "The New Generation of Effective Optical Dermatology and Tissue Repair Treatments"

MONTREAL, Oct. 3, 2013 /CNW Telbec/ - On the heels of receiving its Medical Device License from Health Canada for the Klox Biophotonic System for the treatment of acne vulgaris, (also known as the Lumigel Cleanse System), KLOX Technologies Inc. ("KLOX") announced that Dr. Lise Hébert, President and CEO, will be presenting today at BioContact Québec being held in Québec City, Canada at 11:00 AM (EDT).  Dr. Hébert will be discussing KLOX's Lumigel Cleanse System as well as the science-based technology behind it and its vast potential in skin rejuvenation and tissue repair.

DATEBOOK:

BIOCONTACT QUEBEC'S 19^th EDITION, A BIOPHARMACEUTICAL PARTNERSHIP SYMPOSIUM - October 3^rd, 2013, Québec City

• The New Generation of Effective Optical Dermatology and Tissue Repair Treatments
  
  Presenter: Dr. Lise Hébert, President and CEO, KLOX Technologies Inc.
  
  Thursday, October 3^rd, - 11:00 AM / 12:00 PM (EDT), Hôtel Château Laurier (Salle de la Colline), Québec City

ON TWITTER
KLOX Technologies corporate account: @KLOXTech

Acne market overview: a lucrative market lacking a non-systemic and non-invasive solution
Of the 150 million people worldwide who suffer from acne, a chronic and often debilitating dermatological condition, over 20% suffer from moderate to severe forms. The multi-billion dollar global acne market currently lacks non-systemic and non-invasive treatments with strong efficacy and good safety profile. KLOX is confident that its system will be able to fill this significant void with a new technology that is supported by clinically-significant and conclusive trial results. KLOX plans to introduce the system in the market as the Lumigel Cleanse™ and Lumiderm™ Light.

About KLOX Technologies: Leveraging light-based biophotonic technologies                        
www.kloxtechnologies.com/en/investor-relations
KLOX is a privately-owned company focused on the development and commercialization of a unique, non-invasive biophotonic technology using a primary device consisting of a multiple LED lighting system that interacts with an oxygen-rich gel containing light-trapping molecules. KLOX's cosmetics and medical devices are destined for the rapidly growing aesthetics, dermatological, tissue repair and dental markets.

About BioContact Québec
BioContact Québec is an international biopharmaceutical partnership symposium that brings together top researchers, experts, investors, government officials, and nearly 100 pharmaceutical companies from Canada, the United States and Europe.

SOURCE: KLOX Technologies Inc.

Roch Landriault
NATIONAL Public Relations
[phone]
[email protected]